Alexion
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH
Phil Taylor
Alexion, complement therapeutics, EHA 2021, Haematology, iptacopan, Novartis, rare disease, Soliris, Ultomiris
0 Comment
News/ News/ Sales and Marketing
UK competition watchdog probes AstraZeneca, Alexion merger
Phil Taylor
Alexion, AstraZeneca, competition law, M&A, UK
0 Comment
Apellis set to take on Alexion as FDA clears PNH drug Empaveli
Phil Taylor
Alexion, Apellis Pharma, AstraZeneca, Empaveli, rare disease, Soliris, Ultomiris
0 Comment
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS
Phil Taylor
Alexion, AstraZeneca, Health Technology Assessment, HEOR, nephrology, NHS, rare disease, Scotland, Soliris, Ultomiris
0 Comment
CHMP backs Roche’s Enspryng for rare nerve disease NMOSD
Phil Taylor
Alexion, CHMP, enspryng, EU, neurology, rare disease, Roche, Soliris
0 Comment
NICE recommends Alexion’s long-acting Ultomiris for PNH
Richard Staines
Alexion, AstraZeneca, market access, NICE
0 Comment
Sales and Marketing/ Views & Analysis/ Views and analysis